NasdaqGS:GHHealthcare
Guardant Health (GH) Could Be 3% Undervalued After 48% Revenue Growth
Guardant Health (GH) recently reported a 48% year over year revenue increase in Q1 2026 and raised full year revenue guidance to US$1.30b to US$1.32b, putting its oncology and screening growth in focus.
See our latest analysis for Guardant Health.
Guardant Health’s recent Q1 update comes after a sharp shift in sentiment, with the stock posting a 90 day share price return of 71.56% and a 1 year total shareholder return of 231.68%, signalling strong momentum despite some short term...